Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma.
- 1 June 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 8 (6), 476-482
- https://doi.org/10.1161/01.hyp.8.6.476
Abstract
Combining high-performance liquid chromatography with radioimmunoassay enabled the precise measurement of different angiotensins and their metabolites in plasma. Peptides were extracted from 2 ml of plasma by reversible adsorption to phenylsilyl-silica, separated by isocratic high-performance liquid chromatography, and quantitated by radioimmunoassay using a sensitive but suitably cross-reacting angiotensin II antiserum. For the C-terminal angiotensin II metabolites (2-8)heptapeptide, (3-8)hexapeptide, and (4-8)pentapeptide, overall recoveries of 10 fmol peptide added to 1 ml of plasma were (mean +/- SD), 74 +/- 6, 68 +/- 8, and 67 +/- 11%, respectively. The detection limit for these peptides in plasma was 0.2 fmol/ml. Blanks were below the detection limits. In eight seated normal subjects treated for 4 days with enalapril, 20 mg p.o., q.d., angiotensin II metabolites tended to decrease during the 4 postdrug hours. However, their cumulated concentration in relation to octapeptide increased from 54 to 163% on Day 1 and from 62 to 103% on Day 4. After 4 hours of converting enzyme inhibition with enalapril there was still a close correlation between plasma renin activity and angiotensin-(1-8)octapeptide level (r = 0.83, p less than 0.05) and between blood angiotensin I and angiotensin-(1-8)octapeptide levels (r = 0.86, p less than 0.01). Adding angiotensin I in vitro raised the angiotensin-(1-8)octapeptide levels after incubation at 4 degrees C for 4 hours. Thus, immunoreactive "angiotensin II" does not disappear after converting enzyme inhibition largely because of the cumulated contribution of cross-reacting metabolites and partly because of in vitro generation of true angiotensin II.This publication has 14 references indexed in Scilit:
- True versus immunoreactive angiotensin II in human plasma.Hypertension, 1985
- Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.British Journal of Clinical Pharmacology, 1984
- Identification of a human neutrophil angiotension II-generating protease as cathepsin G.Journal of Clinical Investigation, 1982
- Tonin, an esteroprotease from rat submaxillary glandsBiochimica et Biophysica Acta (BBA) - Enzymology, 1981
- Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.British Journal of Clinical Pharmacology, 1981
- Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.Heart, 1980
- Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.Hypertension, 1979
- Angiotensin III: (DES-Aspartic Acid-1)-Angiotensin II. Evidence and speculation for its role as an important agonist in the renin - angiotensin system.Circulation Research, 1975
- An Easy Radioimmunological Microassay of Renin Activity, Concentration and Substrate in Human and Animal Plasma and Tissues Based on Angiotensin I Trapping by AntibodyJournal of Clinical Endocrinology & Metabolism, 1974